The in vivo efficacy of JBH492 was investigated in multiple preclinical models of lymphoid malignancies, chosen to cover a range of various CCR7 expression levels, including a panel of 11 DLBCL patient derived xenograft (PDX) models….RNAseq and flow cytometry reveal high CCR7 expression in lymphoid neoplasms, including chronic lymphocytic leukemia (CLL), B-cell and T-cell non-Hodgkin's lymphoma (NHL)...Preclinical characterization of JBH492 demonstrates potent, target-dependent cytotoxic activity....Our translational data support the hypothesis that JBH492 may have the potential to become a promising first-in-class ADC for the treatment of CCR7-expressing lymphoid malignancies.